CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Glasgow预后评分（GPS）和CAR-HEMATOTOX（CAR-HT）评分可识别在接受细胞免疫治疗时具有免疫介导毒性及早期死亡高风险的MM患者。然而，这些评分与接受T细胞重定向双特异性抗体（bsAb）治疗患者结局的关联尚不明确。这项多中心回顾性研究探讨了基线GPS和CAR-HT评分与126例接受bsAb治疗的MM患者结局的关联。总体而言，19%被判定为GPS高风险，但并未出现毒性或死亡率增加。相反，CAR-HT高风险患者的感染发生率更高且生存更差，提示需要采取积极的感染防控策略。
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy.
However, their association with outcomes in patients receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the association of baseline GPS and CAR-HT scores with outcomes in 126 MM patients treated with bsAb.
Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high-risk CAR-HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
